ClinicalTrials.gg
RecruitingNCT07687966CBP0276-OpdUpdated Jul 7, 2026

CBP-0276 to Reduce Opioid Use in Adults Undergoing Major Orthopedic Surgery

A Phase 2 interventional study of CBP-0276 and Placebo for CBP-0276 in Hip or Knee Replacement, sponsored by Clarent Biopharma, Inc.. Recruiting at 1 site in Mexico. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-07.

Sponsored by Clarent Biopharma, Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jun 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started May 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
40 Years to 75 Years
Sex
All
01

Study summary

Randomized, double-blind, clinical study to evaluate the safety and efficacy of CBP-0276 at doses of 600 mg/day in reducing opioid use in pain management in adult patients undergoing major orthopedic surgery. Subjects will be allocated in 2 groups. One group will receive oxycodone (standard of care) + CBP-0276 at a dose of 600 mg, orally once daily for 28 days. A second group will receive oxycodone (standard of care) + placebo for CBP-0276, orally once daily for 28 days

Read the detailed description

Randomized, Phase 2, Proof-of-concept, double-blind, parallel-group, placebo controlled clinical study to evaluate the safety and efficacy of CBP-0276 at doses of 600 mg/day in reducing opioid use in pain management in adult patients undergoing major orthopedic surgery. Subjects will be allocated in 2 groups. One group (n=40) will receive oxycodone (standard of care) + CBP-0276 at a dose of 600 mg, orally once daily for 28 days. A second group (n=40) will receive oxycodone (standard of care) + placebo for CBP-0276, orally once daily for 28 days. Primary outcome is the reduction on the number of oxycodone tablets required to controlled the moderate to severe pain management during the 28 days post-major orthopaedic surgery. Secondary and Exploratory outcomes are: A) Number of days where the use of oxycodone is required; B) Changes in quality of life according to the WHOQOL-BREF score, from baseline and at 28 days post-surgery; C) The number of oxycodone tablets required for pain management at day 15 post-surgical; D) Frequency and intensity of pain at day 28 post-surgery and at 3 months of post-surgical follow-up; E) Changes on inflamatory cytokines between baseline and end of treatment (day 28) Characteristics of the subject to be enrolled included age between 40 and 75y, male or female, BMI 18.5 to 35, under surgery of hip or knee replacement.

02

Conditions studied

  • Hip or Knee Replacement
03

In context

Lead sponsor

Clarent Biopharma, Inc. is the lead sponsor of 4 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men or women
  • Age between 40 and 75 years (inclusive)
  • Body weight between 50 and 90 Kg
  • Post-surgical patient of major orthopedic surgery, with opioid treatment (oxycodone) at discharge by treating physician
  • Physical status of
  • Be able and willing to read, understand, sign, and date the Informed
  • Consent Form prior to entering the study.
  • Woman of childbearing age with effective , not pregnant, not on breastfeeding, not pregnancy plans during the development of the study, , defined by cessation of menstruation for at least 12 consecutive months and confirmed by serum FSH levels > 40 mIU/mL and estradiol \< 20 pg/mL or surgically sterile (with hysterectomy, bilateral salpingectomy, or bilateral oophorectomy) and not undergoing in vitro fertilization or other fertility treatments)
  • Men agreed to use contraception or remain abstinent (when this is the subject's usual and preferred lifestyle)Be willing to complete all study visits and procedures.

Exclusion criteria

Exclusion criteria:

  • History of respiratory depression, severe bronchial asthma, , or acute and/or severe hypercepnia and cor pulmonale.
  • History of gastrointestinal motility disorders (e.g., severe reflux esophagitis, gastroparesis, severe irritable bowel syndrome, active inflammatory bowel disease, and paralytic ileus).
  • History of depression, seizures, and epilepsy.
  • Uncontrolled hypertension: systolic BP ≥160 mmHg or diastolic BP ≥100 mmHg confirmed by at least two measurements.
  • History of allergic reactions, anaphylactic reactions, severe systemic , or any allergic reaction that, in the opinion of the Principal Investigator or his /her delegate, is likely to be exacerbated by the study drug (RAP-103 and oxycodone).
  • History of or positive HIV test result (HIV 1-2 antibodies).
  • History of infection or positive hepatitis C virus (HCVAb) antibody screening result.
  • Current (HBV) infection (defined as positive for HepBsAg and/or HepBcAb). Subjects with immunity to hepatitis B from prior natural infection (defined as HepBsAg negative, HepBcAb positive, and HepBsAb positive) or vaccination (defined as HepBsAg negative, HepBCAb negative, and HepBSAb positive) are eligible to participate in the study.
  • Transcutaneous oxygen saturation (SpO₂) \<90%.
  • Patients with severe liver or kidney disease.
  • Patients with , neoplasms, or HIV infection.
  • Active substance use disorder (SUD) or within the previous 12 months, including opioid, alcohol, benzodiazepines, or any other substance with potential for abuse.
  • Patients with the use of antipsychotic medications.
  • Any clinical condition that makes it difficult to self-assess pain.
  • Recent opioid use (14 days prior recruitment).
  • Previous exposure to RAP-103 or DAPTA (T-Peptide) at any time in your life.
  • Abnormal and results at the discretion of the Principal investigator (or his/her delegate) in the laboratory tests and of visit 0. Laboratory values out of range and determined to be not clinically significant at the discretion of the Principal Investigator or his/her delegate may be repeated on one occasion, the subject may be enrolled if the repeated value is within the normal range.
  • Participation in any other study with drugs, biologics, medical devices, or treatment with an investigational product or therapy approved for investigational use within 30 days or 5 halflives at visit 0.
  • Any other condition that, in the judgment of the PI or Sponsor, determines that the subject is not suitable to participate in the study.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    CBP-0276 600mg QD

    First group (n=40) will receive oxycodone (standard of care) + CBP-0276 at a dose of 600 mg, orally once daily for 28 days.

    Drug: CBP-0276

  • Placebo comparator
    Placebo for CBP-0276

    Second group (n=40) will receive oxycodone (standard of care) + placebo for CBP-0276, orally once daily for 28 days

    Drug: Placebo for CBP-0276

Interventions

  • Oxycodone CBP-0276 orally 600mg QD, orally once a day for 30 days

  • DrugPlacebo for CBP-0276

    Oxycodone (standard of care) + placebo for CBP-0276, orally once daily for 30 days

06

What researchers measure

Primary outcomes

  1. Frequency of oxycodone use

    Number of oxycodone tablets required to controlled the moderate to severe pain management after hip or knee replacement.

    Time frame: 28 days

Secondary outcomes

  1. Oxycodone total requirements

    Number of days where the use of oxycodone is required

    Time frame: 28 days

  2. Changes on Quality of Life

    Changes in quality of life according to the WHOQOL-BREF score, from baseline and at 28 days post-surgery. This is a 26-item self-report questionnaire that assesses an individual's subjective perception of their well-being and quality of life over the previous two weeks. The raw item scores are converted into transformed domain scores on a standardized scale from 0 to 100. 0 represents the lowest possible perceived quality of life, meanwhile 100 represents the highest.

    Time frame: 28 days

  3. Number of oxycodone tablets required

    The number of oxycodone tablets required for pain management at day 15 post-surgical

    Time frame: 28 days

  4. Changes on Pain Intensity

    Frequency and intensity of pain evaluated by visual analoge scale (VAS) at day 28 post-surgery and at 3 months of post-surgical follow-up, where 0 is no pain and 10 is the most severy level of pain

    Time frame: 28 days

  5. Chnages on inflamatory cytokines

    Changes on inflamatory cytokines between baseline and end of treatment (day 28)

    Time frame: 28 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Apfelbaum JL, Chen C, Mehta SS, Gan TJ. Postoperative pain experience: results from a national survey suggest postoperative pain continues to be undermanaged. Anesth Analg. 2003 Aug;97(2):534-540. doi: 10.1213/01.ANE.0000068822.10113.9E. PubMed 12873949 ↗
  • Mattia C, Coluzzi F, Sonnino D, Anker-Moller E. Efficacy and safety of fentanyl HCl iontophoretic transdermal system compared with morphine intravenous patient-controlled analgesia for postoperative pain management for patient subgroups. Eur J Anaesthesiol. 2010 May;27(5):433-40. doi: 10.1097/EJA.0b013e3283349d82. PubMed 20186064 ↗
  • Glare P, Aubrey KR, Myles PS. Transition from acute to chronic pain after surgery. Lancet. 2019 Apr 13;393(10180):1537-1546. doi: 10.1016/S0140-6736(19)30352-6. PubMed 30983589 ↗
  • DeWire SM, Yamashita DS, Rominger DH, Liu G, Cowan CL, Graczyk TM, Chen XT, Pitis PM, Gotchev D, Yuan C, Koblish M, Lark MW, Violin JD. A G protein-biased ligand at the mu-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine. J Pharmacol Exp Ther. 2013 Mar;344(3):708-17. doi: 10.1124/jpet.112.201616. Epub 2013 Jan 8. PubMed 23300227 ↗
  • Padi SSV, Shi XQ, Zhao YQ, Ruff MR, Baichoo N, Pert CB, Zhang J. Attenuation of rodent neuropathic pain by an orally active peptide, RAP-103, which potently blocks CCR2- and CCR5-mediated monocyte chemotaxis and inflammation. Pain. 2012 Jan;153(1):95-106. doi: 10.1016/j.pain.2011.09.022. Epub 2011 Oct 26. PubMed 22033364 ↗
  • Noda M, Tomonaga D, Kitazono K, Yoshioka Y, Liu J, Rousseau JP, Kinkead R, Ruff MR, Pert CB. Neuropathic pain inhibitor, RAP-103, is a potent inhibitor of microglial CCL1/CCR8. Neurochem Int. 2018 Oct;119:184-189. doi: 10.1016/j.neuint.2017.12.005. Epub 2017 Dec 14. PubMed 29248693 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2026 (actual). Primary completion is estimated for Jun 2026, 1 month after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 25, 2026
First posted
Jul 7, 2026
StartActual
May 8, 2026
Primary completionEst.
Jun 30, 2026
CompletionEst.
Sep 30, 2026
Last update
Jul 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07687966
Responsible party
Sponsor
First posted
Jul 7, 2026
Start date
May 8, 2026
Primary completion
Jun 30, 2026 (estimated)
Completion
Sep 30, 2026 (estimated)
Last update
Jul 7, 2026

Study contacts

Pedro Gutiérrez Castrellón, MD, PhD
Contact
pedro.gutierrez@elemental.org.mx
+525554198746
Diana M Andrade Platas, MD
Contact
diana.andrade@elemental.org.mx
+525535209755
Jorge González Thompson, MD
principal investigator · Innovacion y Desarrollo de Estrategias en Salud SA de CV

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CBP-0276

Start the discussion